CurrentBlue Cross Blue Shield - MassachusettsPolicy N/A

Laser interstitial thermal therapy (LITT) for neurological indications — Coverage Criteria

This policy governs coverage and prior authorization requirements for MR-guided laser interstitial thermal therapy (LITT) for neurological indications (e.g., primary/metastatic brain tumors, radiation necrosis, drug-resistant epilepsy) for Blue Cross Blue Shield - Massachusetts members.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyLaser interstitial thermal therapy (LITT) for neurological indications — Coverage Criteria

Policy CodePolicy N/A

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionObtain precertification/prior authorization if the procedure is performed inpatient; outpatient prior authorization varies by product.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

investigationalcoverage stance

61736, 61737investigational CPTs

precert requiredinpatient auth

~28references

Coverage Determinations

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Not covered (Investigational) — All Indications

Covered when ALL of the following are met:

Investigational stance: Laser interstitial thermal therapy (LITT) is considered investigational for all neurological indications, including but not limited to primary or metastatic brain tumors, radiation necrosis, and drug-resistant epilepsy.

Applicable to Commercial and Medicare product lines as specified in policy.

Outpatient magnetic resonance–guided laser interstitial thermal therapy (LITT) is listed as not a covered service in several product lines. Specifically, the policy identifies outpatient LITT as not covered for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO BlueSM, and Medicare PPO BlueSM members. Providers should refer to product-specific sections for any variations in prior authorization requirements or inpatient coverage rules.

Several sections of the policy function as reference material and list published studies, systematic reviews, society position statements, and guidance documents relevant to LITT. These reference-only sections summarize the literature on indications such as primary and metastatic brain tumors, radiation necrosis, and drug‑resistant epilepsy but do not by themselves establish new coverage criteria, exclusions, or additional not‑medically‑necessary rules in this policy.

Key referenced sources include multicenter prospective studies, meta-analyses, and professional society position statements (for example, AANS-CNS, AASSFN, Congress of Neurological Surgeons, NCCN, NICE, and CMS guidance) that inform the clinical context but do not change the policy’s investigational coverage stance.

Per this policy, magnetic resonance–guided laser interstitial thermal therapy (LITT) is considered investigational for all neurological indications. As stated in the policy, this includes, but is not limited to, use for primary or metastatic brain tumors, radiation necrosis, and drug‑resistant epilepsy. Because the procedure is classified as investigational, it is considered not medically necessary under this policy and claims for these services are at risk for denial.

Provider Requirements and Impact

Denial Risk

Procedure considered investigational

Laser interstitial thermal therapy (LITT) is considered investigational for all neurological indications (including but not limited to primary or metastatic brain tumors, radiation necrosis, and drug‑resistant epilepsy). Claims for LITT are at risk for denial on that basis.

Prior Authorization

Precertification/Preauthorization required for inpatient

For services described in this policy, precertification/prior authorization IS REQUIRED for all products if the procedure is performed inpatient. Lack of required precertification/prior authorization when performed inpatient may trigger claim denial.

Note

No explicit authorization/denial trigger language

The policy does not include explicit language describing automatic authorization or denial triggers in the reference or policy sections. Providers should be aware that absence of explicit trigger language does not eliminate the investigational determination or prior‑auth requirements and may result in case‑by‑case review.

Documentation Required

Billing and documentation guidance

Providers should report all services using the most up‑to‑date industry‑standard procedure, revenue, and diagnosis codes (CPT, HCPCS, ICD‑10), including applicable modifiers. Include MR guidance details and lesion documentation in operative and radiology reports to support the medical record.

Report services with current CPT/HCPCS/ICD-10 codes and modifiers where applicable
Document MR thermography guidance, probe positioning, ablation parameters, and treated lesion specifics in the record

Note

Outpatient coverage varies by product — often not covered

Outpatient coverage differs by product. The policy lists outpatient LITT as not a covered service for Commercial Managed Care (HMO and POS), Commercial PPO and Indemnity, Medicare HMO BlueSM, and Medicare PPO BlueSM. Check member contract benefits to determine coverage for individual members.

Step Therapy

Step‑therapy / sequencing

No step‑therapy requirements or sequencing rules are specified in the policy or reference materials. Providers should not expect formal step‑therapy criteria for LITT but must still meet prior authorization and documentation expectations where applicable.

Note

Reference guidance and position statements inform coverage considerations

References include society guidance and position statements (AANS‑CNS, AASSFN, Congress of Neurological Surgeons, ASCO‑SNO, NCCN, NICE) and peer‑reviewed studies that inform clinical context and coverage considerations; these should be reviewed when preparing authorization requests and supporting documentation.

Clinical Background

Magnetic resonance–guided laser interstitial thermal therapy (LITT) involves placement of a laser fiber probe through a transcranial burr hole into the target lesion to deliver thermal energy and thermally ablate tissue. The procedure is performed under real‑time MR thermography to monitor thermal dose and control the ablation zone. It is proposed as a minimally invasive alternative for lesions that are surgically inaccessible or located in eloquent brain regions. Reported complications in the literature include neurologic weakness, cerebral edema, hemorrhage, seizures, and electrolyte disturbances; standard MRI contraindications apply.

Key Terms and Definitions

LITT — MR-guided laser interstitial thermal therapy definition

TermMagnetic resonance (MR)-guided laser interstitial thermal therapy (LITT)

Procedure descriptionIntroduction of a laser fiber probe via a transcranial burr hole to deliver thermal energy for targeted ablation of diseased brain tissue under MRI guidance.

MechanismThermal destruction mediated by DNA damage, necrosis, protein denaturation, membrane dissolution, vessel sclerosis, and coagulative necrosis; ablation controlled using real-time MR thermography and actively cooled applicators.

Monitoring and controlProbe position, ablation time, and intensity are controlled under MRI with real-time MR thermography to maintain a sharp thermal border.

Clinical contextUsed for ablation of surgically inaccessible or eloquent-area lesions as a minimally invasive alternative to traditional surgery.

Radiation necrosis — definition and context

TermRadiation necrosis

DefinitionSymptomatic necrotic brain tissue that develops following prior radiotherapy; described in the literature as an indication treated with LITT in some studies.

Clinical relevanceOccurs in surgically inaccessible or eloquent brain areas where minimally invasive approaches such as LITT have been reported as management options.

Complications overlapPatients with radiation necrosis treated with LITT may experience typical post-LITT complications including cerebral edema, weakness, hemorrhage, and seizures.

Drug-resistant epilepsy — referenced ILAE definition citation

ReferenceInternational League Against Epilepsy (ILAE) consensus definition for drug-resistant epilepsy (cited via Kwan et al. in the policy references).

Context in policyThe term 'drug-resistant epilepsy' is referenced in relation to LITT studies and systematic reviews comparing LITT with open surgery or other interventions.

Supporting literatureMultiple systematic reviews and meta-analyses of MRI-guided LITT for drug-resistant epilepsy are cited (see Ekman et al., Brotis et al., and others in the references).

NoteExact phrasing of the ILAE definition is cited but not reproduced in the policy text; the policy references the consensus definition in the bibliography.

OpenPayer

Laser interstitial thermal therapy (LITT) for neurological indications — Coverage Criteria

Coverage Determinations

Billing and Codes

Provider Requirements and Impact

Clinical Background

Key Terms and Definitions

61736	Laser interstitial thermal therapy (LITT) of lesion, intracranial, including burr hole(s), with magnetic resonance imaging guidance, when performed; single trajectory for 1 simple lesion.
61737	Laser interstitial thermal therapy (LITT) of lesion, intracranial, including burr hole(s), with magnetic resonance imaging guidance, when performed; multiple trajectories for multiple or complex lesion(s).